ALNY vs OMER
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. OMER: A biopharmaceutical company bridging commercial success from its ocular surgery product with a clinical-stage pipeline targeting complement-mediated disorders.
Side-by-side fundamentals
| Metric | ALNY | OMER | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $224.53 | $19.12 | |
| Market cap | $30.0B | $1.4B | |
| P/E as of 2026-10-08 | 38.21 | 20.32 | OMER lower |
| Net margin FY2025, SEC XBRL | +8.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +13.5% | n/a | |
| ROE FY2025, SEC XBRL | +39.8% | n/a | |
| ROA FY2025, SEC XBRL | +6.3% | -1.0% | ALNY higher |
| Debt / equity as of 2026-09-03 | 2.02 | 21.55 | ALNY lower |
| Revenue growth (YoY) as of 2026-09-03 | +95.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +4.4% | ALNY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.80 | 1.29 | |
| 1-year return as of 2026-10-08 close | -50.2% | +335.5% | OMER higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.